In this section:

12 March 2019

NICE Approves Two New Biologic Treatments for Psoriasis

The injectable treatments, Cimzia (certolizumab pegol) and Ilumetri (tildrakizumab), get the go ahead from NICE. 

The National Institute for Health and Care Excellence (NICE) has published its final draft guidance recommending the biologic treatments, Cimzia (certolizumab pegol) and Ilumetri (tildrakizumab) as options for treating severe psoriasis in adults in England and Wales, where the condition has not responded to other systemic therapies, or if these treatments are not suitable.

Cimzia (certolizumab pegol)


Cimzia is a biologic treatment which is taken by an injection every 2 weeks (after the 'loading dose' of two injections in each of weeks 0,2 and 4). It blocks tumour necrosis factor-alpha (TNF alpha) a chemical ‘messenger’ in the immune system that signals other cells to cause inflammation.

There is too much TNF alpha in the skin of people with psoriasis, which causes inflammation and can lead to tissue damage. TNF alpha can also lead to increased activity of the immune system by switching on certain white blood cells in the body, called T Cells. Once T cells become overactive they can trigger inflammation and other immune responses, encouraging the development of psoriasis.
 
Cimzia helps lower the amount of TNF alpha to more normal levels, and switches off the inflammatory cycle of psoriasis. This leads to improvement in symptoms for many people who take it.

You can read more about NICE's decision to approve Cimzia here

Ilumetri (tildrakizumab)

Ilumetri is a biologic treatment which is taken by an injection at weeks 0 and 4, and every 12 weeks thereafter. It was initially rejected by NICE in November 2018 as it was not considered to be cost-effective enough. However, following the submission of a new price by the manufacturer, it has subsequently been approved.

Ilumetri blocks the activity of interleukin 23 (IL-23), a type of small protein which controls the growth of white blood cells called T cells. When these T cells become overactive, they can trigger inflammation that is linked to the development of psoriasis.

By blocking the action of IL-23, Ilumetri reduces inflammation and can therefore improve the symptoms associated with psoriasis.

You can read more about NICE's decision to approve Ilumetri here

We will be publishing more information on both Cimzia and Ilumetri soon. In the meantime, please get in touch with us if you have any questions.

The Psoriasis Association is the UK's leading national charity and membership organisation for people affected by psoriasis – patients, families, carers and health professionals Read More >

Get in touch

The Psoriasis Association Dick Coles House 2 Queensbridge Northampton NN4 7BF

Email: mail@psoriasis-association.org.uk

Tel :
01604 251 620
Fax :
01604 251 621
Registered with Fundraising Regulator -

© The Psoriasis Association Charitable Incorporated Organisation Number: 1180666 Scotland: SC039886 Privacy PolicyCookies

Site by Spoken Image | glitterfish

We use cookies to help us provide you with a better service, but do not track anything that can be used to personally identify you.

If you prefer us not to set these cookies, please visit our Cookie Settings page or continue browsing our site to accept them.